Aera Therapeutics Email Format

Biotechnology ResearchMassachusetts, United States51-200 Employees

Aera Therapeutics is a biotechnology research company based in Cambridge, Massachusetts, with a team in the 51-200 range. The company focuses on unlocking the potential of genetic medicines by addressing delivery, identified as the greatest unmet need in the field. It has developed proprietary delivery platforms, including targeted lipid nanoparticles (tLNPs), antibody oligonucleotide conjugates (AOCs), and protein nanoparticles (PNPs), intended to enable next-generation genetic medicines across multiple modalities and disease areas. These platforms are intended to overcome limitations of current delivery technologies and broaden the applications of genetic medicines. Public updates indicate progress, including the February 2023 launch of Aera's Platform delivery technology and leadership appointments in 2025, such as Bill Querbes becoming senior vice president of therapeutic discovery and translational sciences and Paul Conrad becoming chief business and financial officer.

Sign up for free to view info

Company overview Employee directory